This is a contrast between Cellectis S.A. (NASDAQ:CLLS) and Aptinyx Inc. (NASDAQ:APTX) based on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	21.43M	38.18	78.69M	-2.11	0.00
Aptinyx Inc.	6.57M	19.86	53.28M	-1.42	0.00

Table 1 highlights Cellectis S.A. and Aptinyx Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us the net margins, return on equity and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-367.20%	-23%	-18.8%
Aptinyx Inc.	-810.96%	0%	0%

Liquidity

The Current Ratio and a Quick Ratio of Cellectis S.A. are 11.2 and 11.2. Competitively, Aptinyx Inc. has 21.8 and 21.8 for Current and Quick Ratio. Aptinyx Inc.’s better ability to pay short and long-term obligations than Cellectis S.A.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Cellectis S.A. and Aptinyx Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	2	1	2.33
Aptinyx Inc.	0	0	1	3.00

Cellectis S.A.’s upside potential is 80.58% at a $35.25 consensus price target. Competitively the consensus price target of Aptinyx Inc. is $12, which is potential 208.48% upside. The data from earlier shows that analysts belief suggest that Aptinyx Inc. seems more appealing than Cellectis S.A.

Insider and Institutional Ownership

Roughly 29.4% of Cellectis S.A. shares are owned by institutional investors while 74.6% of Aptinyx Inc. are owned by institutional investors. Competitively, insiders own roughly 2.8% of Aptinyx Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
Aptinyx Inc.	-9.41%	0.94%	-76.28%	-76.78%	0%	-67.41%

For the past year Cellectis S.A. has 17.6% stronger performance while Aptinyx Inc. has -67.41% weaker performance.

Summary

On 7 of the 12 factors Aptinyx Inc. beats Cellectis S.A.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.